Autologous gene‑modified T cells engineered with a mesothelin‑targeted CAR; co‑expresses a CD40 agonist and a T‑cell costimulatory agonist to enhance activation, proliferation, persistence, and APC licensing.
Autologous gene‑modified T cells expressing a mesothelin‑targeted CAR that recognizes MSLN on tumor cells and mediates T‑cell activation and cytotoxicity; co‑expression of a CD40 agonist licenses/activates antigen‑presenting cells, and a T‑cell costimulatory agonist augments T‑cell activation, proliferation, and persistence to enhance antitumor efficacy.
YES
DIRECT
MSLN‑CAR T cells bind mesothelin on target cells and directly induce killing via T‑cell effector mechanisms (perforin/granzyme release and death‑receptor pathways), with co‑stimulatory/CD40 agonism enhancing activity.
Autologous gene‑modified T cells engineered with a mesothelin‑targeted CAR; co‑expresses a CD40 agonist and a T‑cell costimulatory agonist to enhance activation, proliferation, persistence, and APC licensing.
Autologous gene‑modified T cells expressing a mesothelin‑targeted CAR that recognizes MSLN on tumor cells and mediates T‑cell activation and cytotoxicity; co‑expression of a CD40 agonist licenses/activates antigen‑presenting cells, and a T‑cell costimulatory agonist augments T‑cell activation, proliferation, and persistence to enhance antitumor efficacy.
NO
INDIRECT
The CD40 moiety is an agonist that activates/licenses APCs via CD40 to enhance T‑cell responses; killing is mediated by the MSLN‑CAR T cells against MSLN+ tumor cells, not against CD40+ cells.
Autologous gene‑modified T cells engineered with a mesothelin‑targeted CAR; co‑expresses a CD40 agonist and a T‑cell costimulatory agonist to enhance activation, proliferation, persistence, and APC licensing.
Autologous gene‑modified T cells expressing a mesothelin‑targeted CAR that recognizes MSLN on tumor cells and mediates T‑cell activation and cytotoxicity; co‑expression of a CD40 agonist licenses/activates antigen‑presenting cells, and a T‑cell costimulatory agonist augments T‑cell activation, proliferation, and persistence to enhance antitumor efficacy.
NO
INDIRECT
The co‑expressed costimulatory agonist activates T cells via their costimulatory receptors to boost CAR‑T function; cytotoxicity is directed by the CAR against mesothelin‑positive tumor cells (perforin/granzyme), not against cells expressing the costimulatory receptor.
Tebentafusp (IMCgp100) is a bispecific ImmTAC T‑cell engager with an affinity‑enhanced TCR that binds the gp100 (PMEL) peptide presented by HLA‑A*02:01 on melanoma cells and an anti‑CD3 domain that recruits and activates T cells, inducing TCR/CD3 signaling, cytokine release, immune synapse formation, and tumor cell lysis.
A soluble ImmTAC that uses an affinity‑enhanced TCR to bind the gp100 (PMEL) peptide presented by HLA‑A*02:01 on melanoma cells and an anti‑CD3 domain to recruit and activate polyclonal T cells, crosslinking tumor cells and T cells to trigger TCR/CD3 signaling, cytokine release, immune synapse formation, and cytotoxic killing of gp100‑expressing tumor cells.
YES
DIRECT
An ImmTAC with an affinity-enhanced TCR binds the gp100 peptide–HLA-A*02:01 complex on target cells and its anti-CD3 domain engages T cells, forming an immune synapse that activates T cells to kill the bound target cell via perforin/granzyme-mediated cytolysis (and related T cell effector mechanisms).
Tebentafusp (IMCgp100) is a bispecific ImmTAC T‑cell engager with an affinity‑enhanced TCR that binds the gp100 (PMEL) peptide presented by HLA‑A*02:01 on melanoma cells and an anti‑CD3 domain that recruits and activates T cells, inducing TCR/CD3 signaling, cytokine release, immune synapse formation, and tumor cell lysis.
A soluble ImmTAC that uses an affinity‑enhanced TCR to bind the gp100 (PMEL) peptide presented by HLA‑A*02:01 on melanoma cells and an anti‑CD3 domain to recruit and activate polyclonal T cells, crosslinking tumor cells and T cells to trigger TCR/CD3 signaling, cytokine release, immune synapse formation, and cytotoxic killing of gp100‑expressing tumor cells.
NO
INDIRECT
Tebentafusp binds CD3ε on T cells to recruit and activate them; the activated T cells then kill gp100–HLA-A*02:01–positive tumor cells via cytolytic mechanisms, not the CD3+ T cells themselves.